Original Article

Acceptance, safety, and impact on quality of life of exergame for elderly patients with neurodegenerative diseases: A systematic review and meta-analysis

Ghina Tsurayya¹*, Teuku F. Duta¹, Muhammad A. Naufal¹, Meulu Alina¹, Chinwe C. Isitua² and Ernest C. Ohanu³

¹Medical Research Unit, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia; ²Department of Biology and Forensic Science, Faculty of Science, Admiralty University of Nigeria, Delta State, Nigeria; ³Department of Medical Laboratory Science, University of Calabar, Calabar, Nigeria

*Corresponding author: tsurayyaghina464@gmail.com

Abstract

The aim of this study was to evaluate the efficacy, safety, adherence, and acceptance of exergame in improving the quality of life (QoL) among elderly patients with neurodegenerative diseases. A systematic search was conducted in PubMed, Embase and Scopus for relevant studies up to 16 March 2023. Quality of the included studies were assessed using Cochrane’s Risk of Bias tool version 2.0. Meta-analysis using a random effect was conducted on outcomes reported at least by two studies to calculate the standard mean difference (SMD) and its 95% confidence interval (CI). The difference of influence between exergame and conventional therapy was judged based on Z- and p-values. Heterogeneity was determined by I²-score. As many as 15 studies were included (n=466 participants) published between 2013–2023. Nine studies had ‘high quality’ five studies had ‘some concerns’, and one had ‘high risk’. Results from meta-analyses suggests that the exergame does significantly not improve the QoL among patients with Parkinson’s diseases. Similarly, no statistically significant difference (p>0.05) of QoL improvement among Alzheimer’s disease patients receiving exergame intervention. No adverse effects were reported to be associated with the intervention, and in fact, the patients experienced reduced fatigue and fear of falling. Patients in intervention group showed high acceptance and adherence to the therapy, which could be attributed to exergame being enjoyable, easy-to-use, and motivational. In conclusion, despite exergame being highly acceptable and relatively safe, the intervention does not improve the QoL of the elderly patients.

Keywords: Acceptance, elderly, exergame, neurodegenerative, quality of life

Introduction

Neurodegenerative diseases affect millions of people due to the increasing aging rate of the worldwide population [1]. They are characterized by the progressive deposition of specific proteins within district areas of the brain and progressive loss of sensory-motor and cognitive functions [2-4]. Out of many different types of neurodegenerative diseases, Alzheimer’s (AD), Parkinson’s (PD), Huntington’s diseases (HD), and multiple sclerosis (MS) are the most prevalent [5].

In general, these diseases have typical symptoms, namely weakness, fatigue, motor impairment, ataxia, dysphagia, urinary complications, sensory loss, depression, cognitive decline, sleep disorders, and so on [6]. These conditions could be developed into severe symptoms
affecting the daily living of the sufferer’s [7,8]. Data suggest that patients with neurodegenerative
disease present lower levels of health-related quality of life (QoL) in emotional, physical, and
social terms than that of the general population [6].

Standard rehabilitation consists of conventional physical training (including aerobic
exercise or other exercises that aim to improve muscle strength, physical function, balance
control, and flexibility) and cognitive training (completing puzzles, painting, drawing, playing
dominoes, crosswords, and playing word games). Unfortunately, conventional rehabilitation is
still considered inefficient and provides a long recovery period [9]. The traditional clinical setting
for therapy is often expensive and suffers from poor adherence. Thus, experts have suggested the
urgency of improving rehabilitation efficacy through innovation and technology.

Exergame is a technology that provides physical and cognitive training simultaneously by
combining exercise and gaming activities. Exergame requires its users to engage in physical
activities and multiple players interaction, where they can share learning experiences and feel
challenged at each difficulty level [10]. Dancing, boxing, batting, running, and puzzle solving
through quests are among many other fun and exciting activities the patients could experience
when using an exergame. Through gamified techniques, exergame allows patients to receive
rehabilitation at home. The gamified therapy performed in the clinic can be installed at the
patient’s home ensuring the continuity of the rehabilitation [11]. Moreover, all people across
generations are interested in playing games [12].

Further, many games have been designed specifically for healthcare services. Different
games are tailored for various disorders according to the requirements of the patients. That is,
the games are customized individually according to the patients’ needs. These exergames are
included in the rehabilitation process since they combine the benefits of gaming as well as
exercising. The virtual reality games facilitate people to substitute their sedentary screen time
with physical activities [13]. Unfortunately, the impacts of exergame on QoL have not been
extensively evaluated and summarized in a frame of a comprehensive review. Herein, a systematic
review and meta-analysis were performed to evaluate the efficacy of exergame in improving the
QoL among patients with neurodegenerative diseases. Safety of exergame and the patients’
acceptance toward this technology were also evaluated.

**Methods**

**Search strategies**
The literature search was performed for randomized control trials published from January 2008
(the first year of exergames studies exists) through March 2023 on three major scientific
literature databases, which are PubMed, EMBASE, and Scopus. It was conducted using the
following keywords: “elderly”, “neurodegenerative”, “Alzheimer’s disease”, “Parkinson’s disease”,
“Huntington’s disease”, “Multiple sclerosis”, “exergame”, “quality of life”, “safety”, and
“acceptance”. Detailed keyword combinations used in this study are presented in Table 1.

**Inclusion criteria**
Inclusion criteria that are considerable for eligibility were based on the PICOS (population,
intervention, control, outcome, and study design) framework. The population was
neurodegenerative patients (Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and
multiple sclerosis) over the average age of 60 years. We included studies with investigated
exergame-based interventions consisting of augmented reality or virtual reality, where the control
group received conventional exercise or no intervention. Outcome measured in this study was
QoL, acceptance, and safety. Only randomized controlled trials (RCTs) were included.

**Exclusion criteria**
The exclusion criteria were as follows: (1) healthy people as the control group; (2) the subject had
other neurodegenerative diseases than Parkinson’s disease, Alzheimer’s disease, Huntington’s
disease or multiple sclerosis; (3) irrelevant outcome; (4) studies published before 2008; (5) severe
sensory impairments (mainly visual, auditory, or color blindness); (6) published in languages
other than English; (7) review article, case report, conference proceedings, and abstract,
editorials, or commentaries; (8) no full access to full-text; and (10) the patients had severe cardiac disease, uncontrolled diabetes, a history of stroke, traumatic brain injury, a seizure disorder, and other severe systemic diseases.

Table 1. Search strategy in each database

<table>
<thead>
<tr>
<th>Database</th>
<th>Search strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed</td>
<td>(old* OR older OR elderly OR aged OR geriatric OR &quot;older people&quot;) AND (exergame OR exergaming OR “virtual reality” OR “virtual world” OR “video game” OR “active video game” OR “human computer interaction” OR “augmented reality” OR “electronic game” OR “active game play” OR “virtual rehabilitation” OR “augmented rehabilitation” OR wii OR Kinect OR “balance board” OR “Dance Dance Revolution” OR “digital exercise”) AND (“quality of life” OR “health-related quality of life” OR “life quality” OR HRQOL OR acceptance OR acceptability OR safety) AND (“alzheimer’s disease” OR alzheimer OR “alzheimer’s dementia” OR “parkinson’s disease” OR “parkinson” OR “huntington’s disease” OR “huntington” OR “multiple sclerosis” OR “demyelinating disease” OR neurodegenerative)</td>
</tr>
<tr>
<td>EMBASE</td>
<td>(TITLE-ABS-KEY((old* OR elderly OR aged OR geriatric OR &quot;older people&quot;))) AND TITLE-ABS-KEY(exergam* OR “virtual reality” OR “virtual world” OR “video game” OR “active video game” OR “human computer interaction” OR “augmented reality” OR “electronic game” OR “active game play” OR “virtual rehabilitation” OR “augmented rehabilitation” OR wii OR Kinect OR “balance board” OR “dance dance revolution”) AND TITLE-ABS-KEY(“quality of life” OR “health related quality of life” OR “life quality” OR HRQOL OR Acceptance OR Acceptability OR Safety)) AND TITLE-ABS-KEY(“Alzheimer’s disease” OR alzheimer OR “alzheimer’s dementia” OR “parkinson’s disease” OR “parkinson” OR “huntington’s disease” OR “huntington” OR “multiple sclerosis” OR “demyelinating disease” OR neurodegenerative))</td>
</tr>
<tr>
<td>SCOPUS</td>
<td>(old*:ti,ab,kw OR elderly:ti,ab,kw OR aged:ti,ab,kw OR geriatric:ti,ab,kw OR ‘older people’:ti,ab,kw) AND (exergam*:ti,ab,kw OR ‘virtual reality’:ti,ab,kw OR ‘virtual world’:ti,ab,kw OR ‘video game’:ti,ab,kw OR ‘active video game’:ti,ab,kw OR ‘human computer interaction’:ti,ab,kw OR ‘augmented reality’:ti,ab,kw OR ‘electronic game’:ti,ab,kw OR ‘active game play’:ti,ab,kw OR ‘virtual rehabilitation’:ti,ab,kw OR ‘augmented rehabilitation’:ti,ab,kw OR wii:ti,ab,kw OR ‘balance board’:ti,ab,kw OR ‘dance dance revolution’:ti,ab,kw OR ‘digital exercise’:ti,ab,kw) AND (‘quality of life’:ti,ab,kw OR ‘health-related quality of life’:ti,ab,kw OR ‘life quality’:ti,ab,kw OR ‘HRQOL’:ti,ab,kw OR ‘acceptance’:ti,ab,kw OR ‘acceptability’:ti,ab,kw OR ‘safety’:ti,ab,kw) AND (‘alzheimer disease’:ti,ab,kw OR alzheimer:ti,ab,kw OR ‘alzheimer’s dementia’:ti,ab,kw OR ‘parkinson disease’:ti,ab,kw OR ‘parkinson’:ti,ab,kw OR ‘huntington disease’:ti,ab,kw OR ‘huntington’:ti,ab,kw OR ‘multiple sclerosis’:ti,ab,kw OR ‘demyelinating disease’:ti,ab,kw OR neurodegenerative:ti,ab,kw) AND [2008-2023]/py</td>
</tr>
</tbody>
</table>

Screening and study selection

Two authors (G.T & M.A) adapted Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines that can be accessed through (http://www.prisma-statement.org) into the process of literature screening and selection of this study. The 404 total studies we searched were imported to Zotero 6 (zotero.org) and duplicates removed were performed automatically. Titles and abstracts of studies were screened to identify potential studies that met the inclusion criteria. The full texts of these studies were retrieved and independently assessed for eligibility. The full texts of these studies were independently retrieved and reviewed for eligibility. Thirteen studies were included to be extracted for the assessment of the QoL, safety, and acceptance. Hand-picked articles that met the criteria were also included in this systematic review. In the end, fifteen studies were concluded and extracted into primary outcomes.

Data extraction

Study data were also extracted by the same reviewer as the screening. The extracted data included QoL, safety and acceptance. We also extracted the relevant study information, including the first author, country/location, age, sample size (male/female), stage of disease (according to Hoehn and Yahr scale), interventions, the duration and length of intervention, the comparison group, assessments, and outcome measures. Any ambiguity (e.g. The different selections or judgment of outcome measures) met by these two reviewers was discussed with the help of the third reviewer (T.F.D).
Outcomes measures
The primary outcome that was assessed in this systematic review was the impact on QoL, safety, and acceptance for using exergame as a beneficial exercise method rather than the conventional one. There are many variants for neurodegenerative QoL measurement tools. For Parkinson’s disease, 39-item Parkinson’s Disease questionnaire (PDQ-39) and 5-dimension questionnaire developed by EuroQol (EQ-5D) were used. As for the Alzheimer’s disease, QoL in Alzheimer’s disease (QoL-AD) was used. The tools have different focuses, domains, and ways to measure and interpret the responses. Safety was assessed by a number of adverse events such as falls, muscle soreness, excessive fatigue during the follow-up period, reduction of the fatigue severity scale (FSS), and a specially designed questionnaire. Acceptance defined by the willing of the patient to use and engage with the exergame. The outcomes were described and extracted into tables.

Quality assessment of studies
The two reviewers (M.A.N & G.T) separately evaluated the studies in the same timeline, April 2023. The studies that met the inclusion criteria after systematic screening adopted R.O.B 2.0, which recommended a tool to assess the risk of bias in randomized trials included in Cochrane Reviews. 5 domains were assessed to define the risk of bias.

Data synthesis and analysis
Meta-analysis was only performed for outcomes that are reported in at least two studies. Forest plots were generated on the software developed by Cochrane Collaborations – RevMan version 5.4.1. Mean differences and standard deviation with 95% confidence interval (CI) and p-value were extracted from the study intervention versus control. Meta-analysis using a random effect was carried out on outcomes reported at least by two studies to calculate the standard mean difference (SMD) and its 95% confidence interval (CI). The difference of influence between exergame and conventional therapy was judged based on Z- and p-values. Heterogeneity was determined by I² score. P-value <0.05 was considered as statistically significant and I² >50% — highly heterogenous.

Results
Search result and study characteristics
The PRISMA flow diagram for the included studies based on the eligibility criteria in this review has been presented in Figure 1. As many as 15 studies met the inclusion criteria and were included in this review participated by a total number of 466 patients (59% male) ranging from 10 to 25 participants per group. All of the included studies were randomized clinical trials. Among these studies, the average age of participants ranged from 61 to 81 years old. Studies were conducted in Australia, Italy, Brazil, Taiwan, Switzerland, Hungary, and the United States of America. Summary of the characteristics of the included studies along with their outcomes has been presented in Table 2. We included 3 meta-analyses: (1) PDQ-39 QoL of Parkinson’s disease consists of 9 studies, (2) EQ-5D QoL of Parkinson’s disease consists of 2 studies, and (3) AD-QoL of Alzheimer’s disease that consist of 2 studies.
Quality appraisal

The results from the quality appraisal of the included studies have been presented in Figure 2. As many as nine studies were found to have passed all Cochrane’s risk of bias criteria, indicating them as high-quality studies [14,15,17–19,22,23,25,26]. Five studies were found to have some concerns [16,21,24,27,28], where three of them were derived from missing outcome data [16,21,24], while two others were because of deviation from the intended intervention and biased measurement [27,28], respectively. A study was marked with a high risk of bias due to missing outcome data [20].

Figure 2. Traffic light plot (a) and summary plot (b) for RoB 2.0 assessment results.
<table>
<thead>
<tr>
<th>Author, Year [Ref]</th>
<th>Country</th>
<th>Disease</th>
<th>Characteristic</th>
<th>Treatment</th>
<th>QoL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen et al., 2017 [14]</td>
<td>Australia</td>
<td>Parkinson's Disease</td>
<td>n= 19 Age, year: 67.5±7.3 M/F: 12/7 MMSE: 28.8±1.0</td>
<td>n= 19 Age, year: 68.4±8.5 M/F: 11/8 MMSE: 28.6±1.1</td>
<td>↔</td>
</tr>
<tr>
<td>Pazzaglia et al., 2020 [15]</td>
<td>Italy</td>
<td>Parkinson's Disease</td>
<td>n= 25 Age, year: 72±7 M/F: 18/7</td>
<td>n= 26 Age, year: 70±10 M/F: 17/9</td>
<td>↑</td>
</tr>
<tr>
<td>Ribas et al., 2016 [16]</td>
<td>Brazil</td>
<td>Parkinson's Disease</td>
<td>n= 10 Age, year: 61.7±6.83 M/F: 4/6 Stage: I-III MMSE: 27.5 ± 1.5</td>
<td>n= 10 Age, year: 60.20 ± 11.29 M/F: 4/6 Stage: I-III MMSE: 27.5 ± 0.75</td>
<td>↔</td>
</tr>
<tr>
<td>Yuan et al., 2020 [17]</td>
<td>Taiwan</td>
<td>Parkinson's Disease</td>
<td>n= 12 Age, year: 67.8 ± 5.5 M/F: 2/10 Stage: I-III MMSE: 28.5 ± 1.7</td>
<td>n= 12 Age, year: 66.5 ± 8.8 M/F: 9/3 Stage: I-III MMSE: 26.0 ± 2.6</td>
<td>↔</td>
</tr>
<tr>
<td>Santos et al., 2019 [18]</td>
<td>Brazil</td>
<td>Parkinson's Disease</td>
<td>n= 13 Age, year: 61.7 ± 7.3 M/F: 11/2 Stage: I-III MMSE: 28.5 ± 1.7</td>
<td>n= 14 Age, year: 64.5 ± 9.8 M/F: 11/3 Stage: I-III MMSE: 26.0 ± 2.6</td>
<td>↑</td>
</tr>
<tr>
<td>Jaggi et al., 2023 [19]</td>
<td>Switzerland</td>
<td>Parkinson's Disease</td>
<td>n= 21 Age, year: 71.89 ± 9.09 M/F: 12/7 Stage: I-IV MMSE: 27.79 ± 1.55</td>
<td>n= 21 Age, year: 72.86 ± 10.14 M/F: 15/6 Stage: I-IV MMSE: 27.57 ± 2.71</td>
<td>NR</td>
</tr>
<tr>
<td>Yang et al., 2016 [20]</td>
<td>Taiwan</td>
<td>Parkinson's Disease</td>
<td>n= 10 Age, year: 72.5±8.4 M/F: 7/4 Stage: II-III MMSE: 27.5±4.0</td>
<td>n= 10 Age, year: 75.4±6.3 M/F: 7/5 Stage: II-III MMSE: 27.5±2.5</td>
<td>↔</td>
</tr>
<tr>
<td>Alves et al., 2018 [21]</td>
<td>Brazil</td>
<td>Parkinson's Disease</td>
<td>n= 9 Age, year: 58.89±11.16 M/F: 9/0 Stage: I-III MMSE: 27.11±2.8</td>
<td>n= 9 Age, year: 61.67±10.74 M/F: 8/1 Stage: I-III MMSE: 25.44±2.29</td>
<td>↑</td>
</tr>
<tr>
<td>Author, Year [Ref]</td>
<td>Country</td>
<td>Disease</td>
<td>Characteristic</td>
<td>Control</td>
<td>Treatment</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------</td>
<td>---------</td>
<td>----------------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>Alves et al., 2018 [21]</td>
<td>Brazil</td>
<td>Parkinson's Disease</td>
<td>n=9</td>
<td>n=9</td>
<td>Xbox KinectTM, 2x/weeks, 5 weeks, on medication</td>
</tr>
<tr>
<td>Ferraz et al., 2018 [22]</td>
<td>Brazil</td>
<td>Parkinson's Disease</td>
<td>n=20</td>
<td>n=20</td>
<td>Kinect, 50-minutes/session, 3x/week for 8 weeks</td>
</tr>
<tr>
<td>Tollar et al., 2018 [23]</td>
<td>Hungary</td>
<td>Parkinson's Disease</td>
<td>n=25</td>
<td>n=25</td>
<td>Exergame use Xbox 360 core system, 1 hour/ session over 5 weeks, three-5-week-long waves</td>
</tr>
<tr>
<td>Pedreira et al., 2013 [24]</td>
<td>Brazil</td>
<td>Parkinson's Disease</td>
<td>n=16</td>
<td>n=15</td>
<td>Exergame using Nintendo Wii, 40 minutes/session, 3 days/week for 4 weeks.</td>
</tr>
<tr>
<td>Liao et al., 2014 [25]</td>
<td>Taiwan</td>
<td>Parkinson's Disease</td>
<td>n=12</td>
<td>n=12</td>
<td>VR-based Wii Fit exercise + treadmill training, 2 sessions/week, 6 weeks</td>
</tr>
<tr>
<td>Fontoura et al., 2017 [26]</td>
<td>Brazil</td>
<td>Parkinson's Disease</td>
<td>n=10</td>
<td>n=10</td>
<td>VR + conventional physiotherapy, 60 minutes/session, 2 sessions/week, 5 weeks</td>
</tr>
<tr>
<td>Padala et al., 2017 [27]</td>
<td>USA</td>
<td>Alzheimer's Disease</td>
<td>n=15</td>
<td>n=15</td>
<td>Wii-Fit program, 30 minutes/session, 5 days/week for 8 weeks</td>
</tr>
<tr>
<td>Padala et al., 2012 [28]</td>
<td>USA</td>
<td>Alzheimer's Disease</td>
<td>n=11</td>
<td>n=11</td>
<td>Wii-fit training, 30 minutes/session, 5 times/week for 8 weeks</td>
</tr>
</tbody>
</table>

M/F, male/female; MMSE, mini-mental state examination; NR, not reported
↔, not significant; †, significant
Quality of life among Parkinson’s disease patients based on PDQ-39 score
The results of the random effect meta-analysis of the QoL-based on PDQ-39 have been presented in Figure 3. The effect of exergame therapy on QoL was assessed in nine studies [14,15,17–19,22,23,25,26] according to PDQ-39 overall mean score. The effect of exergame therapy on QoL favored the experimental group but was not statistically significant (n= 9, SMD= -0.08, 95%CI: -0.31–0.16, p= 0.53). The I² of this analysis was unobservable (0%).

![Figure 3. The result of exergame in alleviating quality of life in Parkinson disease patients using PDQ-39 tools](https://via.placeholder.com/150)

Quality of life among Parkinson’s disease patients based on Euroqol-5D score
The results of the random effect meta-analysis of the quality based on Euroqol-5D only assessed in 2 studies [22,23] and are presented in Figure 4. The effect of exergame therapy on QoL favored the experimental group but was not statistically significant (n= 2, SMD= -0.27, 95%CI: -0.79–0.24, p= 0.30). The I² of this analysis was no more than 50% (35%).

![Figure 4. The result of exergame in alleviating quality of life in Parkinson’s disease patients using Euroqol-5D tools](https://via.placeholder.com/150)

Quality of life among Alzheimer’s disease patients
The results of the random effect meta-analysis of the quality based on the QoL-AD were only assessed in 2 studies [27,28] and have been presented in Figure 5. The effect of exergame therapy on QoL favored the experimental group but was not statistically significant (n= 2, SMD= -0.21, 95%CI: -0.33–0.76, p= 0.44). The I² of this analysis was abandoned (0%).

![Figure 5. The result of exergame in alleviating quality of life in Alzheimer’s disease patients using AD-QoL tools](https://via.placeholder.com/150)

Safety
Six studies performed the observation on the occurrence of adverse events. All studies reported the absence of adverse events during the intervention [14,16,17,19,25,27].
Acceptance and adherence
Acceptance was associated with exergame being enjoyable, easy-to-use, and motivational [14]. Low attrition was observed in an RCTs which was associated with easy-to-use characteristic of the exergame [19]. The adherence rate was high as reported in three studies [14,19,27], where some studies reported the adherence rate of 97% [19] and 80% [27]

Discussion
Exergame is a new technological invention that has been lately designed for medical purposes. This gaming technology has recently been used to treat patients with PD and other neurologic disorders [24]. It combines video-game-based training with augmented virtual reality (VR) and is intended to be engaging and challenging, therefore stimulating motivation and increasing exercise adherence [29]. Further advantages of exergaming are the possibility to adapt to the level of exercise difficulty and to provide online visual and/or verbal feedback during the exercise. All these aspects are important to optimize motor learning in individuals with neurologic disorders.

In this present systematic review, fourteen studies assessing the QoL were included. Twelve of which reporting about Parkinson’s disease and the other two – Alzheimer’s disease [14,15,24–28,16–23]. Most of Parkinson’s disease studies used PDQ-39 and EQ-5D. While the tools for assessing the QoL in Alzheimer’s patients used QoL-AD. The tools have different focuses, domains, and approaches in measuring and interpreting the responses. PDQ-39 was designed to measure the impact of Parkinson’s disease in various aspects that affect the individual’s life involving eight different domains which are mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The higher score of PDQ-39 indicates, the lower QoL [30]. Additionally, EQ-5D assesses only five domains consisting of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The higher score of EQ-5D indicates the better QoL [31]. Equally important, QoL-AD evaluates five domains including physical health, mood, functional abilities, social support, and financial resources with a higher score suggesting a better QoL.

In this present meta-analysis, we found that exergame did not significantly improve the QoL as compared to control. According to the individual study employing, significant improvement of QoL among elderly with neurogenerative diseases was reported in 8 studies [15,18,21,22,24–27], while the insignificant results were reported in the other 5 studies [14,16,17,23,28]. We also noticed the presence of probable bias deriving from the imbalance baseline in two studies [16,24]. Previously, a meta-analysis was carried out to assess the improvement of QoL among elderly with neurogenerative diseases [32]. As a comparison, we included more studies than the previous meta-analysis [32]. Our present meta-analysis results are in accordance with the previous meta-analysis. [32]. Moreover, the results of our meta-analysis are also in accordance with a study that assessed the QoL on different neurological diseases [33].

There were six studies that reported the safety of using an exergame, for instance, fall, muscle soreness, fatigue, and so on [14,16,17,19,25,27]. All the studies revealed that there were no adverse events found when using the exergame as a rehabilitation. There were no adverse events reported within the studies whether using exergame with sitting up, walking, or moving methods. One of the included study witnessed that exergame had a lower value of fatigue in Parkinson’s disease than conventional rehabilitation, and enhanced the confidence level of patients for avoiding falls while intervention [16]. Participants also felt a reduction in fear of falling during the intervention, where the console can be set with safety settings [27].

High adherence rate was found in three studies means that they are comfortable doing the task of exergames, [14,19,27], even some of them doing more than the prespecified task as order and low attrition indicates high acceptability for people with a neurodegenerative disorder. Through open-ended and close-ended interviews, it was revealed that participants felt the exergame was easy, safe, well-integrated, enjoyable, easy to learn, and motivated to complete the next task. However, studies reported that some patients had difficulties in following the exergame therapy, such as having insufficient space at home for the exergame [14]. In another study, the patients complained about the complexity, cumbersome, and need for technical support for the exergame therapy [19].
This present study is the first in reporting the pooled results from studies participated by elderly population. As limitations, the data acquired are limited and cannot be used to infer a conclusion for the whole neurodegenerative disease. For example, there are studies reporting Parkinson’s disease and Alzheimer’s disease, multiple sclerosis, and Huntington’s Disease but were excluded because the participants > 60 years old. Moreover, the limitation in data is also contributed by the small sample size of the included studies.

Conclusions
Exergames are not significantly different from conventional rehabilitation in improving the QoL. However, exergame is still considered a promising modality in rehabilitating patients with neurodegenerative disease attributed to its easy-to-use and entertaining nature. Moreover, the exergame was found to have high acceptance and safety for the elderly to use. To ensure maintaining the interest of its users, we recommend the game developer improve the visualization, game scenarios, and movement variety. We also highly suggest further research to develop an exergame that requires minimum space, so it will not burden participants living in small houses. Investigation with a larger sample size is highly recommended in the future.

Ethics approval
Not required.

Acknowledgments
None.

Competing interests
All the authors declare that there are no conflicts of interest.

Funding
This study received no external funding.

Underlying data
All data underlying the results are available as part of the article and no additional source data are required.

How to cite

References


